BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 55.20 0.00%
BMRN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.69B
- P/E (TTM)
- 149.19
- Forward P/E
- 8.34
- EPS (TTM)
- $0.37
- Dividend yield
- None
- 52-week range
- 49.26 – 70.98
- Day range
- 54.76 – 56.60
- Volume / Avg
- 2.08M / 2.00M
- Beta
- —
- Shares outstanding
- 193.57M
- Next earnings
- Oct 26, 2026
52-week range
BMRN stock today
On Oct 7, BMRN ended the session at $55.20, shedding $1.02 (1.81%), versus the S&P 500's 0.22% decline. Shares are 22.2% below their 52-week high of $70.98, set on Aug 12, 2026 and 12.1% above the 52-week low of $49.26, in the middle of the past year's range. BMRN is down 7.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 0.9%.
At 149.2x trailing earnings, BioMarin Pharmaceutical trades in line with the peer-group median of 136.8x. Its forward P/E of 8.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 26; analysts expect EPS of $1.13.
Summary generated from market data by MetaCap's automated system. Methodology
About BioMarin Pharmaceutical
Company profileBioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Alexander Hardy
- Headquarters
- San Rafael, CA
- Employees
- 3,221
- IPO year
- 1999
- Website
- biomarin.com
Financial highlights
Full financialsIn fiscal 2025, BioMarin Pharmaceutical generated $3.22 billion in revenue, up 12.9% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $348.9 million (-18.3% year over year), for a net margin of 10.8% versus a median of 6.9% in the prior 5 years. Gross margin was 77.7% (down from 79.7%) and operating margin 12.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Growth | +12.87% | +17.97% | +15.42% | +13.53% | -0.76% |
| Net income | $348.90M | $426.86M | $167.65M | $141.56M | $-64.08M |
| EPS (diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
Analyst forecast
ForecastConsensus (27 analysts)
buy
Avg. price target
$91.62+65.98%
- Strong buy 6
- Buy 14
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 26, 2026
- EPS estimate
- $1.13
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $0.23 vs —
BMRN news
All BMRN newsBioMarin Pharmaceutical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs BMRN |
| MDGLMadrigal Pharmaceuticals Inc. | 487.72 | -1.76% | $11.27B | vs BMRN |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs BMRN |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs BMRN |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs BMRN |
| CORTCorcept Therapeutics Incorporated | 119.60 | +0.03% | $12.93B | vs BMRN |
| BBIOBridgeBio Pharma Inc. | 66.50 | -0.69% | $13.00B | vs BMRN |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs BMRN |
Indexes, lists and sector
BioMarin Pharmaceutical stock FAQ
What is BioMarin Pharmaceutical's stock price today?
BMRN last traded at $55.20 as of Oct 7, 4:00 PM EDT, down 1.81% on the day. Prices are delayed at least 15 minutes.
When is BioMarin Pharmaceutical's next earnings date?
BioMarin Pharmaceutical is expected to report earnings on Monday, October 26, 2026. Analysts expect EPS of $1.13.
What is BMRN's P/E ratio?
BMRN trades at a trailing P/E ratio of 149.19 and a forward P/E of 8.34, compared with a median of 136.8 for its closest peers.
Who is BioMarin Pharmaceutical's CEO?
Mr. Alexander Hardy is the chief executive officer of BioMarin Pharmaceutical Inc., which has about 3,221 employees.
What is the BMRN 52-week high?
The 52-week high for BMRN is $70.98 and the 52-week low is $49.26. The stock is currently 22.2% below its high.